Taclonex Scalp is approved by the FDA for scalp psoriasis
Warner Chilcott and Leo Pharma announc the FDA approval of a new combination suspension for psoriasis of the scalp.
A new combination topical suspension containing calcipotriene 0.005% and betamethasone dipropionate 0.064% has been approved by the Food & Drug Administration. The new product will be marketed as Taclonex Scalp, from Warner Chilcott and Leo Pharma, and is indicated for the treatment of moderate to severe psoriasis vulgaris of the scalp in adults. According to the manufacturers, scalp psoriasis is a very common form of the condition, affecting at least half of all people who have psoriasis. The companies expect to launch the new suspension in the second half of 2008.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
